Home | Welcome to Contract Pharma   
Last Updated Wednesday, August 20 2014
Print

Search Results for 'biopharma'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Contract Service Directory Companies

View All Companies »


Search Results:

Top 25 Pharma and Biopharma Report
Published July 21, 2014
Big Pharma continues to face the impact of competitive pressures, fluctuating currencies, the patent cliff, and pipeline surprises, all of which were reflected in financial results last year. Read More »
Biopharma CMO Update
By William Downey , HighTech Business Decisions
Published June 3, 2014
Increased demand is driving higher capacity utilization and more partnerships Read More »
Top 10 Biopharma Report
Published July 16, 2013
Our annual look at the 10 biggest players in the Biopharmaceutical marketplace Read More »
Cangene bioPharma
By Patrick DePalma, Director of Business Development
CANGENE bioPharma is a contract manufacturer, providing fill/finish and support services. Located in Baltimore, MD, U.S., close to the FDA, CANGENE bioPharma is highly compliant, having successfully passed inspections from numerous regulatory agencie… Read More »
Baxter BioPharma Solutions
By Donna Abear
Company Description BioPharma Solutions, a business unit of Baxter, partners with pharmaceuti… Read More »
Top 10 Biopharma Companies
By Gil Y. Roth, Editor
Published July 18, 2012
Our annual look at the 10 biggest players in the Biopharmaceutical marketplace Read More »
Top 50 (or so) Biopharma Products
By Ronald A. Rader
Published July 18, 2012
Ranking the top 57 biopharma products by 2011 revenues Read More »
The Top 50 Biopharma Products
By Ronald A. Rader
Published July 14, 2011
A list of the best-selling biopharma products from 2010 Read More »
Top 25 Pharma and Biopharma Report
Published July 21, 2014
Big Pharma continues to face the impact of competitive pressures, fluctuating currencies, the patent cliff, and pipeline surprises, all of which were reflected in financial results last year.  Payers around the world are demanding lower cost dru… Read More »
Published June 14, 2011
Array BioPharma will restructure in an effort to extend its financial resources to focus on the development of key clinical programs: ARRY-520, a KSP inhibitor for multiple myeloma, ARRY-614, a p38 / Tie-2 inhibitor for myelodysplastic syndrome, and MEK162, a MEK inhibitor for cancer in co-development with Novartis. Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On